Key Takeaways
- Margins troughed, recovery promised: Gross margins hit a ~10-year low around 57% as the company consumed high-cost raw material inventory built during COVID-era shortages. Management expects normalization toward historical 67–68% levels "towards the end of the year."
- The inventory overhang is clearing: The 6–9 month buffer of expensive raw materials, procured to hedge supply-chain risk, has now been consumed. With input prices softening, the margin benefit should begin to flow through from Q1 FY24.
- Custom synthesis pipeline is the strongest ever: Two large projects have entered commercial supply, and management reports seeing "never so many opportunities" from big pharma, underpinning the ₹1,200–1,500 crore bet on the Kakinada greenfield site.
- Generic API demand is temporarily suppressed: Dosage-form customers are destocking large COVID-era inventories before expiry, crashing near-term API demand and prices. Once destocking completes, demand and pricing are expected to stabilize and improve.
- What to watch next quarter: The pace of gross margin recovery as lower-cost raw materials enter the P&L, the revenue contribution from the two new custom synthesis projects, and any signs that generic API destocking is ending.
Margin Walk & Raw Material Transition
- The inventory trap: Raw material costs stayed elevated because inventory procured 6–12 months ago at peak prices, during shortages, was still being consumed on a first-in, first-out basis. Process efficiencies actually improved, so the margin compression is almost entirely an input-cost story that is now unwinding.
- Mix amplified the pain: Material consumption reached 42% of sales in Q4 due to a shift in product mix, and the generics:custom synthesis ratio swung to 59:41, both outside management's control and both depressing the gross margin line.
- Other expenses also rose: Higher other expenses partly reflect building and equipment upgradation at older facilities, built in 1995–96, to meet current GMP, safety, and environmental standards.
- The transition is underway: The current quarter already reflects a blend of higher-cost and lower-cost materials as prices transition; management sees a "slightly improving situation from Q1 onward."
- Pricing pressure added to the squeeze: Generic market pricing pressure also contributed to the margin impact, though management says it is impossible to quantify because it is a combination across many products.
Dr. Murali K Divi: "It's difficult to say exactly when on quarter-on-quarter, but we should be able to see that towards the end of the year."
Custom Synthesis: The Growth Engine
- Two projects hit commercial reality: One sartan project entered commercial production and supply during the quarter. A second large custom synthesis project completed qualifications, supplied, and is now ramping up production; both are expected to reflect in revenue from coming quarters.
- Contrast media manufacturing has begun: Commercial manufacturing for a custom synthesis project in collaboration with big pharma, focused on contrast media production, has started. The global contrast media market is growing at a minimum 10% annually, requiring 200–300 tons of extra capacity per product per year, forcing customers to either install new capacity or outsource.
- The outsourcing thesis is structural: Divi's holds low-cost capacity, ready technologies, DMFs in place, and an iodine recovery cost advantage. Management aims to become the leader in contrast media active ingredients in the next 2–3 years.
- Gadolinium shift creates new openings: The company is heavily involved with customers and its own R&D on new MRI compounds as the industry shifts from gadolinium to other metals; processes are developed for some compounds, and discussions are underway with the 2–3 global buyers.
- Pipeline depth is unprecedented: Management states it is seeing several other custom synthesis opportunities from big pharmas and has "never seen so many opportunities," a statement that underpins the scale of the Unit 3 investment.
Dr. Murali K Divi: "We are seeing several other opportunities in custom synthesis projects from big pharmas, never seen so many opportunities."
Generic API: Destocking, Then Recovery
- The destocking drag: After COVID, dosage-form companies built large inventories that are now approaching expiry. Those companies are fighting to clear stocks, crashing generic dosage-form prices and reducing near-term demand for APIs.
- The recovery logic: Once destocking completes, those same companies will need APIs again. Management expects prices to stabilize and demand to improve in coming quarters, though no specific timeline was given.
- Capacity expansion bets are placed: For generic products where capacity was expanded to become the #1 or #2 player, qualifications are complete and commercial sales have started. Full benefits are expected in 4–8 quarters as end-customer qualifications progress.
- The $20B patent expiry opportunity (2023–2025): The first focus is on APIs; drug master files have been submitted, with the objective to make APIs, be ready for patent expiry, and supply for qualification and regulatory submissions.
Dr. Murali K Divi: "After the COVID impact, there are huge stocks of dosage forms and the dosage form companies' generics, they're fighting for getting rid of the stocks before the expiry date. And hence there is a crash in the prices of generic dosage forms and less demand for the generic APIs because they don't need, first they want to get rid of. But once that happens, they need APIs again. So I expect the prices to stabilize and we should see improvement in the coming quarters."
Unit 3 (Kakinada): The Next Decade's Foundation
- Construction is in full swing: All clearances have been obtained, and fast-track construction activity began in early April across the full 500-acre site, with production buildings, utility buildings, and the whole site under active development.
- Phase 1 product strategy is a capacity unlock: Unit 3 will initially manufacture nutraceutical APIs and advanced intermediates/starting materials. This frees up GMP-inspected buildings at Unit 1 and Unit 2 for new custom synthesis and generic opportunities, with benefits visible from FY25.
- Phase 1 commercialization timeline: Expected by the end of calendar year 2024.
- Phase 2 is in discussion: Management is in discussions to determine the investment scope for Phase 2, but the first target is Phase 1 implementation.
- The investment reflects long-term confidence: Management explicitly ties the ₹1,200–1,500 crore Phase 1 commitment to confidence in products, technology, and opportunities for the next 3, 5, and 10 years.
Dr. Murali K Divi: "Having done all this now, we are very comfortable in looking at for the next three years, five and 10 years. Otherwise, I wouldn't invest INR 1,200 crores to INR 1,500 crores in Unit 3..."
Operational Context & Competitive Position
- Capacity utilization is healthy: Plants are running at 77–80%, so the margin pressure is not a fixed-cost absorption problem. Some capacity previously dedicated to COVID drugs is being reallocated, a process that takes time.
- Green Chemistry is non-negotiable: Management frames the adoption of Green Chemistry principles, new technologies to improve productivity, and resource conservation (water, energy, solvents, rare metals) as a must for doing business with US, Europe, and big pharma today.
- Supply chain is normalizing: Positive developments in sea and airfreight costs during Q4, stability in raw material procurement, and reduced dependency on China due to domestic supplier base diversification.
- The mix will stay rangebound: Management expects the generics:custom synthesis ratio to remain in the 40:60 to 60:40 range and does not foresee 20:80 or 80:20 shifts, as the ratio fluctuates based on customer demand and product launches outside their control.
- No sky-is-falling moment: Management pushed back on the idea of an unprecedented business condition, attributing the margin trough to the general course of product mix, inventory consumption, and the abrupt disappearance of the one-time COVID-drug opportunity, all of which played out within three to four months.
Dr. Murali K Divi: "There is nothing that happened like sky is falling down. So there's nothing unprecedented thing that happened. I think it's the general course that took place where always I used to say for the last several years, you should not judge the company by quarter-on-quarter..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin normalization | Return toward historical levels of 67–68% | "Towards the end of the year" (FY24) |
| Raw material cost improvement | Benefits from softening input prices to begin flowing through | From Q1 FY24 onward |
| New custom synthesis revenue | Two large projects (one sartan, one unnamed) to reflect in revenue | "Coming quarters" |
| Unit 3 Phase 1 commercialization | Production to begin at Kakinada greenfield site | End of calendar year 2024 |
| Unit 1/2 capacity unlock | Freed-up GMP buildings to host new custom synthesis and generic products | Benefits visible from FY25 |
| Generic capacity expansion payoff | Full benefits from products where capacity was expanded to become #1/#2 | 4–8 quarters as end-customer qualifications progress |
| Generic API pricing recovery | Stabilization and improvement after dosage-form destocking ends | "Coming quarters" |
| Double-digit revenue growth | Ex-COVID one-time opportunity baseline | Ongoing expectation |
| Corporate tax rate | Normalization as SEZ benefits phase out | ~25–27% over next 10–15 years |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated total revenue | ₹2,017 cr, vs ₹2,571 cr in Q4 FY22 |
| Constant currency revenue growth | -32% YoY |
| Material consumption | 42% of sales revenue, vs 38–39% historically (per an analyst's math) |
| Profit before tax | ₹466 cr |
| Profit after tax | ₹321 cr |
| Exports share | ~90% of revenue |
| Exports to US and Europe | ~68% of revenue |
| Product mix (generics:custom synthesis) | 59:41 |
| Nutraceutical business revenue | ₹150 cr |
| Forex loss | ₹4 cr |
| Capitalized assets | ₹480 cr |
| Capital work in progress | ~₹212 cr as of March 31, 2023 |
| Cash on book | ₹4,136 cr as of March 31, 2023 |
| Receivables | ₹1,793 cr as of March 31, 2023 |
| Inventories | ₹3,000 cr as of March 31, 2023 |
| Capacity utilization | ~77% to 80% |
| Unit 3 Phase 1 capex plan | ₹1,200 cr to ₹1,500 cr |
| Expected corporate tax rate | ~25% to 27% over next 10–15 years as SEZ benefits phase out |